SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 (Suppl. 1): 7481.
  • 2
    Yoshida H, Tateishi R, Arakawa Y et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425430.
  • 3
    George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729738.
  • 4
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975982.
  • 5
    Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346355.
  • 6
    Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 11051109.
  • 7
    Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
  • 8
    Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 11001104.
  • 9
    Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798801.
  • 10
    Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol. Res. 2010; 40: 449460.
  • 11
    Afdhal NH, McHutchison JG, Zeuzem S et al. Hepatitis C pharmacogenetics: state of the art in. Hepatology 2010; 53: 336345.
  • 12
    Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 24172428.
  • 13
    Poordad F, Bronowicki JP, Gordon SC et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 60818 e1-5.
  • 14
    Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 24052416.
  • 15
    Akuta N, Suzuki F, Sezaki H et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372380.
  • 16
    Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 7781.
  • 17
    McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580593.
  • 18
    McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 19
    Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470477.
  • 20
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 17021708.
  • 21
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 2004; 350: 22652271.
  • 22
    Matsuyama N, Mishiro S, Sugimoto M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol. Res. 2003; 25: 221225.
  • 23
    Tsukada H, Ochi H, Maekawa T et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009; 136: 17961805.
  • 24
    Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872874.
  • 25
    Wang JH, Zheng X, Ke X et al. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol. J. 2009; 6: 46.
  • 26
    Montes-Cano MA, Caro-Oleas JL, Romero-Gomez M et al. HLA-C and KIR genes in hepatitis C virus infection. Hum. Immunol. 2005; 66: 11061109.
  • 27
    Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 13381345, 45 e1–7.
  • 28
    Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can. J. Gastroenterol. 2007; 21: 447451.
  • 29
    Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450456.
  • 30
    Busch MP, Glynn SA, Stramer SL et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006; 46: 469475.
  • 31
    Shiffman ML, Mihas AA, Millwala F et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am. J. Gastroenterol. 2007; 102: 761766.
    Direct Link:
  • 32
    Thompson AJ, Muir AJ, Sulkowski MS et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120129.
  • 33
    Rallon NI, Naggie S, Benito JM et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F2329.
  • 34
    Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 15771585, 85 e1–3.
  • 35
    Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317324.
  • 36
    Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821827, 7 e1.
  • 37
    Sakamoto N, Nakagawa M, Tanaka Y et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J. Med. Virol. 2011; 83: 871878.
  • 38
    Yu ML, Huang CF, Huang JF et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 713.
  • 39
    Moghaddam A, Melum E, Reinton N et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746754.
  • 40
    Asselah T, De Muynck S, Broet P et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol. 2012; 56: 527532.
  • 41
    Antaki N, Bibert S, Kebbewar K et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J. Viral Hepat. 2012; 20: 5964.
  • 42
    Abdo AA, Al-Ahdal MN, Khalid SS et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol. Int. 2013; 7: 533538.
  • 43
    Antaki N, Bibert S, Kebbewar K et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012; 61: 16401641.
  • 44
    Seto WK, Tsang OT, Liu K et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J. Viral Hepat. 2013; 20: 470477.
  • 45
    Ragheb M, Nemr N, Kishk R. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int. 2013 Sep 16; doi: 10.1111/liv.12321 [Epub ahead of print].
  • 46
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999; 340: 12281233.
  • 47
    Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 1996; 334: 16911696.
  • 48
    Duggal P, Thio CL, Wojcik GL et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann. Intern. Med. 2013; 158: 235245.
  • 49
    Grebely J, Petoumenos K, Hellard M et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 12161224.
  • 50
    Tillmann HL, Thompson AJ, Patel K et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 15861592, 92 e1.
  • 51
    Grebely J, Page K, Sacks-Davis R et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection. Hepatology 2014; 59: 109120.
  • 52
    Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 265274.
  • 53
    Mangia A, Santoro R, Copetti M et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J. Hepatol. 2013; 59: 221228.
  • 54
    Fabris C, Falleti E, Cussigh A et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 2011; 54: 716722.
  • 55
    Abe H, Ochi H, Maekawa T et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 2010; 53: 439443.
  • 56
    Noureddin M, Wright EC, Alter H et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58: 15481557.
  • 57
    Barreiro P, Pineda JA, Rallon N et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J. Infect. Dis. 2011; 203: 16291636.
  • 58
    Bochud PY, Bibert S, Kutalik Z et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384394.
  • 59
    Marabita F, Aghemo A, De Nicola S et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 11271134.
  • 60
    Akuta N, Suzuki F, Seko Y et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012; 56: 21342141.
  • 61
    Miura M, Maekawa S, Kadokura M et al. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol. Int. 2012; 6: 386396.
  • 62
    Joshita S, Umemura T, Katsuyama Y et al. Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum. Immunol. 2012; 73: 298300.
  • 63
    Asahina Y, Tsuchiya K, Nishimura T et al. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J. Gastroenterol. 2013 Jul 17: doi: 10.1007/S00535-013-0858-2 [Epub ahead of print].
  • 64
    Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 11951206.
  • 65
    Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 12071217.
  • 66
    Jacobson IM, Catlett I, Marcellin P et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J. Hepatol. 2011; 54 (Suppl. 1): S542.
  • 67
    Pol S, Aerssens J, Zeuzem S et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J. Hepatol. 2011; 54 (Suppl. 1): S6.
  • 68
    Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421429.
  • 69
    Fried MW, Buti M, Dore GJ et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-Naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 19181929.
  • 70
    Sulkowski MS, Asselah T, Lalezari J et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 21432154.
  • 71
    McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 12921303.
  • 72
    Bota S, Sporea I, Sirli R, Neghina AM, Popescu A, Strain M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin. Drug Investig. 2013; 33: 325331.
  • 73
    Lawitz E, Rodriguez-Torres M, Stoehr A et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J. Hepatol. 2013; 59: 1117.
  • 74
    Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216224.
  • 75
    Chayama K, Takahashi S, Toyota J et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742748.
  • 76
    Chu TW, Kulkarni R, Gane EJ et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790795.
  • 77
    Zeuzem S, Soriano V, Asselah T et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 2013; 369: 630639.
  • 78
    Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003; 4: 6977.
  • 79
    Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 6368.
  • 80
    Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. U. S. A. 2008; 105: 70347039.
  • 81
    Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 15481563.
  • 82
    Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499509.
  • 83
    Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 18881896.
  • 84
    Asahina Y, Izumi N, Hirayama I et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008; 134: 13961405.
  • 85
    Asahina Y, Tsuchiya K, Muraoka M et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 2029.
  • 86
    Abe H, Hayes CN, Ochi H et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol. 2011; 54: 10941101.
  • 87
    Thomas E, Gonzalez VD, Li Q et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978988.
  • 88
    Watanabe T, Sugauchi F, Tanaka Y et al. Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 2013; 62: 13401346.
  • 89
    Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 2013; 144: 414425 e7.
  • 90
    Yoshio S, Kanto T, Kuroda S et al. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus. Hepatology 2013; 57: 17051715.
  • 91
    Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013; 45: 164171.
  • 92
    Bibert S, Roger T, Calandra T et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 2013; 210: 11091116.